Medtronic (NYSE: MDT) reported first-quarter fiscal 2027 adjusted earnings per share of $1.45, surpassing the analyst consensus estimate of $1.39 by 4.32 percent.

The medical technology giant also posted quarterly sales of $9.756 billion, beating the consensus estimate of $9.545 billion. Sales rose 13.73 percent from $8.578 billion in the same period last year, while earnings per share increased 15.08 percent from $1.26 per share.

What the Numbers Show

The divergence between revenue growth and earnings growth highlights improved operational efficiency or margin expansion during the quarter. While revenue grew 13.73 percent, adjusted EPS grew at a faster clip of 15.08 percent. This suggests that cost management or favorable mix shifts contributed to profitability beyond simple volume growth.

Furthermore, the company beat both revenue and earnings estimates, indicating stronger-than-expected demand or execution in its core markets. The 2.21 percent beat on sales and 4.32 percent beat on EPS suggest robust underlying business momentum.

Portfolio Growth Drivers

Cardiovascular sales grew 19.5%, or 18.9% organically, to $3.927 billion. Cardiac Rhythm Management sales rose 15%, while Cardiac Ablation Solutions surged 88%. Neuroscience revenue climbed 10.3%, or 9.3% organically, to $2.678 billion. Cranial and Spinal Technologies grew 13%, including low-20s growth in enabling technology. Altaviva also helped drive 15% growth in Pelvic Health.

Medical Surgical sales increased 10%, or 10.2% organically, to $2.279 billion. Surgical sales rose 9%, while Acute Care & Monitoring grew 14%. Diabetes revenue increased 16.9%, or 14.9% organically, to $843 million.

Fiscal 2027 Outlook Raised

Medtronic raised its fiscal 2027 adjusted earnings guidance from $5.90-$6 per share to $5.94-$6 per share. The new range compares with the $5.95 consensus estimate. The company also lifted its organic revenue growth forecast to 7.25% to 7.75%, up from its previous range of 6.75% to 7.25%.

For the second quarter, Medtronic expects adjusted earnings of $1.32 to $1.34 per share. The midpoint falls below the consensus estimate of $1.34.

Strategic Investments in Robotics and Structural Heart

Medtronic announced an approximately $700 million strategic investment in Cornerstone Robotics. The agreement includes rights to distribute Cornerstone’s Sentire Surgical System in select markets outside the U.S. where it has regulatory approval. Medtronic plans to offer Sentire alongside its Hugo robotic-assisted surgery system. Sentire has received market approval in China, the European Union and Singapore.

Additionally, Medtronic agreed to invest up to $80 million in Pi-Cardia. The company expects to become the exclusive global distributor of Pi-Cardia’s FDA-cleared ShortCut device in 2027. ShortCut supports complex valve-in-valve transcatheter aortic valve replacement procedures. The agreement gives Medtronic an option to acquire Pi-Cardia after it meets certain milestones. The estimated upfront acquisition price could reach $210 million, plus potential earn-out payments.

Medtronic has announced a strategic partnership with Cornerstone Robotics, committing approximately $700 million to expand its robotic-assisted surgery portfolio globally.

The investment secures distribution rights for Cornerstone's Sentire surgical system in select markets outside the United States where regulatory approval is obtained. This move allows Medtronic to offer a diversified range of surgical solutions alongside its existing Hugo robotic-assisted surgery (RAS) system.

Strategic Portfolio Expansion

Medtronic will distribute Sentire in tandem with Hugo, creating a unique multi-port portfolio of robotic solutions. The two platforms are designed to be complementary, providing surgeons and health systems with greater choice and flexibility tailored to diverse clinical settings and procedural needs.

The partnership aims to address the current limitation in global adoption of robotic-assisted surgery, which remains in the single digits. By expanding access through multiple platforms, Medtronic seeks to reach more patients worldwide while offering health systems varied economic models and clinical options.

Key Deal Terms

What the Numbers Show

The $700 million commitment represents a significant capital allocation toward market expansion rather than immediate revenue generation. By acquiring distribution rights rather than full ownership, Medtronic leverages this investment to diversify its product offering against the backdrop of low global adoption rates for robotic surgery. This strategy positions the company to capture a larger share of the growing minimally invasive surgery market by addressing varied economic and clinical requirements across international health systems.